Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
- ClinicalTrials.gov Identifier: NCT02628067
- Protocol Number: 16-030
- Principal Investigator: James Mier
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required